A Russian pharmaceutical company has begun building Europe's largest biopharmaceutical plant, with plans not only for import substitution but also export to Western countries.

"The plant, beginning from the design stage, takes into account all modern requirements of both European regulating bodies (EMEA) and FDA, the body responsible for regulating pharmaceutical companies in the US," a representative of the company told Russian news site Lenta.ru.

...